drugset
Drugs / ZG005
last change 3 days ago re-read 2 minutes ago

ZG005

Developed for
neoplasm · hepatocellular carcinoma · biliary tract cancer · cancer · cervical cancer · cervical carcinoma · lymphoma · neuroendocrine carcinoma
+2 more · non-small cell lung carcinoma · small cell lung carcinoma
Investigated by
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Changsha Taihe Hospital

Trials 14 · a red edge is where a trial was stopped

today NCT07099547 · Ph 2 NCT07080216 · Ph 1/2 NCT07038096 · Ph 1/2 NCT07142837 · Ph 1/2 NCT06927687 · Ph 2 NCT06903377 · Ph 1/2 NCT06938880 · Ph 1/2 NCT06883526 · Ph 1/2 NCT06558227 · Ph 2 NCT06372626 · Ph 1/2 NCT06239298 · Ph 1/2 NCT06241235 · Ph 1/2 NCT06233994 · not/applicable NCT06233292 · Ph 1/2
202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/210 trials
Phase 1/2 NCT07080216 Sep 2025 → Aug 2027 expected cervical cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT07038096 Sep 2025 → Sep 2027 expected small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT07142837 Sep 2025 → Oct 2027 expected neoplasm Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting No outcome recorded
Phase 1/2 NCT06903377 May 2025 → Apr 2027 expected non-small cell lung carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT06938880 May 2025 → May 2027 expected neoplasm Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT06883526 May 2025 → Apr 2027 expected lymphoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT06372626 May 2024 → Jul 2026 overdue neuroendocrine carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT06239298 May 2024 → Mar 2026 neoplasm Suzhou Zelgen Biopharmaceuticals Co.,Ltd Unknown No outcome recorded
Phase 1/2 NCT06241235 Mar 2024 → May 2026 cervical carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Unknown No outcome recorded
Phase 1/2 NCT06233292 Jun 2022 → Jan 2026 cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd Unknown No outcome recorded
Phase 23 trials
Phase 2 NCT07099547 Dec 2025 → Dec 2027 expected biliary tract cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase 2 NCT06927687 Jun 2025 → May 2027 expected neoplasm Suzhou Zelgen Biopharmaceuticals Co.,Ltd Active not recruiting No outcome recorded
Phase 2 NCT06558227 Oct 2024 → Sep 2026 expected hepatocellular carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting No outcome recorded
Phase not applicable1 trial
— NCT06233994 Jan 2024 → Jan 2026 hepatocellular carcinoma Changsha Taihe Hospital Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as ZG005 “ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion” NCT06241235 ↗
13

NCT06883526 ↗

NCT06233292 ↗

NCT06558227 ↗

NCT07142837 ↗

NCT06372626 ↗

NCT06239298 ↗

NCT06938880 ↗

NCT07038096 ↗

NCT06233994 ↗

NCT06927687 ↗

NCT06903377 ↗

NCT07099547 ↗

NCT07080216 ↗
Route Intravenous “intravenous infusion” NCT06233292 ↗